tradmap

CRON Cronos Group

$3.35 +1.52%

Data as of close

Cannabis Stocks

Healthcare · Medicinal Chemicals & Botanical Products

Cronos Group (CRON) is a healthcare company in the Medicinal Chemicals & Botanical Products industry, with a market capitalization of $1.2 billion. Shares last traded at $3.35, 6.9% below their 52-week high. Over the past year the stock is up 37.0%. CRON trades at a price-to-earnings ratio of 17.64, above the Medicinal Chemicals & Botanical Products median of 12.16. Net profit margin is 39.1%, above the peer median of -8.8%. Revenue grew 24.6% year over year.

Market Cap
$1.2B
Shares Out
368.4M
EPS (TTM)
$0.19
P/E (TTM)*
17.64
P/S Ratio
6.89
P/B Ratio
1.15
Dividend / Share
—
Dividend Yield
—
52-Week High
$3.60
52-Week Low
$2.28
Volume (venue)
41,050
Avg Vol (3m, venue)
71,882.778

* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.

Performance

1W
+1.06%
1M
+4.04%
3M
+19.22%
6M
+26.42%
YTD
+26.89%
1Y
+37.01%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
54.09
SMA (50)
$3.30
SMA (200)
$2.86
Price vs SMA50
+1.42%
Price vs SMA200
+17.13%
ATR (14)
$0.09

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$179M
Net Income
$70M
Gross Margin
45.9%
Operating Margin
-1.4%
Net Margin
39.1%
Return on Equity
6.5%
Return on Assets
5.9%
Current Ratio
16.18
Debt / Equity
0.06
Revenue Growth (YoY)
+24.6%

Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-06-30. Source: SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 $0.09 2026-08-06
Q1 2026 $0.04 2026-05-11
Q4 2025 (derived) -$0.01 2026-02-26
FY 2025 -$0.02 2026-02-26
Q3 2025 $0.07 2025-11-06
Q2 2025 -$0.10 2025-08-07

Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.

Full earnings history →

Medicinal Chemicals & Botanical Products peers

CRON vs 14 industry peers (Medicinal Chemicals & Botanical Products), by market cap. Data as of close

P/E vs peers
17.64 / 12.16 med
+45% premium
P/S vs peers
6.89 / 0.58 med
+1093% premium
Net margin vs peers
39.1% / -8.8% med
above median
1–14 of 14
DFTXDefinium Therapeutics, Inc.$4.4B———-10.70%
RGCRegencell Bioscience Holdings Ltd$3.1B———-5.00%
TRLVTrulieve Cannabis Corp.$2.1B—1.88-41.8%+8.19%
CRONCronos Group$1.2B17.646.8939.1%+1.52%
TLRYTilray Brands$375M—0.39-17.1%+0.40%
SNDLSNDL Inc.$337M———+2.81%
CGCCanopy Growth$288M—1.37-80.0%+4.07%
USNAUSANA HEALTH SCIENCES INC$271M—0.30-2.4%+2.69%
ACBAurora Cannabis$237M———+3.94%
GLASGlass House Brands Inc.$192M—1.05-16.3%+6.85%
NAGENiagen Bioscience, Inc.$190M11.881.4712.4%+2.56%
MDWDMediWound Ltd.$173M———+1.35%
FTLFFITLIFE BRANDS, INC.$78M12.450.776.2%+4.69%
BTMDbiote Corp.$33M5.560.183.2%+1.79%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.